FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3212943903> ?p ?o ?g. }

• W3212943903 endingPage "2425" @default.
• W3212943903 startingPage "2425" @default.
• W3212943903 abstract "Abstract While the majority of follicular lymphoma (FL) patients have an overall survival of nearly 2 decades, a subset of patients has a markedly inferior survival. Across randomized studies, 20% of patients will respond poorly to first-line chemoimmunotherapy and account largely for the early deaths in the larger FL population. This group represents the largest unmet need in FL, for which a precision approach to therapy must be developed. With the development of newer monoclonal antibodies, immunomodulatory agents, therapies targeting molecules downstream of the B-cell receptor and novel cellular strategies, non-cytotoxic treatment has the potential to improve outcomes for patients with early progressing FL. There are several validated clinical factors known to correlate with disease outcome in newly diagnosed FL including age, lactate dehydrogenase, β2-microglobulin and disease extent that have been incorporated in prognostic systems such as FLIPI and FLIPI2. More recently, genetic biomarkers have been identified, including MLL2, EZH2, IRF4, CREPPB, and EPHA7 which reflect the disease biology as well as the impact of the lymphoma microenvironment. The addition of these molecular aberrations to clinical factors has led to the development of the M7-FLIPI as well as a 23-gene score, improving risk prognostication for newly diagnosed FL patients. However, such systems have shown a limited ability to predict progression or relapse within 2 years of chemotherapy. As such, identification of these patients at diagnosis or prior to therapy is currently not possible. S1608 was developed to 1) enable identification of high-risk patients using clinical and molecular markers by validating the m7-FLIPI prognostic system and to 2) identify the novel therapeutic approaches most active in this population. This study is enrolling high-risk patients, refractory to chemoimmunotherapy, and in randomized fashion, comparing novel regimens against additional chemotherapy to identify the most active non-chemotherapeutic strategies for this population. Eligible patients must be 18 years or older with grade 1, 2 or 3a FL and have relapsed or progressed with 2 years of finishing their first course of chemoimmunotherapy. Previous chemotherapy must have been CHOP or bendamustine based. Patients are eligible regardless of anti-CD20 therapy used, whether radiation therapy had been administered and whether or not maintenance therapy was utilized. Note that patients are required to have evidence of progressive disease within 2 years but do not have to be registered within 2 years. These high-risk patients are randomized to 12 months of lenalidomide, umbralisib or additional chemotherapy (for 6 months), all combined with 12 months of obinutuzumab. The primary clinical endpoint is CR rate after 6 cycles, allowing responding patient to proceed with consolidative cellular therapies if desired by the treating physician. Biopsies from diagnosis and at the time of relapse as well as circulating tumor DNA are being collected to prospectively evaluate the m7-FLIPI and to identify additional predictive markers. S1608 is a collaborative effort amongst the SWOG, Alliance and ECOG-ACRIN cooperative groups. The study represents one of the only prospective efforts to characterize early progressing FL and the only randomized trial comparing treatment strategies for this group of follicular lymphoma patients most in need of alternative therapies. Funding: NIH/NCI/NCTN grants U10CA180888, U10CA180819, U10CA180820, U10CA180821; and TG Therapeutics, Inc. Figure 1 Figure 1. Disclosures Barr: Genentech: Consultancy; AstraZeneca: Consultancy; Morphosys: Consultancy; TG Therapeutics: Consultancy; Beigene: Consultancy; Abbvie/Pharmacyclics: Consultancy; Bristol Meyers Squibb: Consultancy; Seattle Genetics: Consultancy; Janssen: Consultancy; Gilead: Consultancy. Link: Novartis, Jannsen: Research Funding; MEI: Consultancy; Genentech/Roche: Consultancy, Research Funding. Flowers: Cellectis: Research Funding; Nektar: Research Funding; Takeda: Research Funding; TG Therapeutics: Research Funding; BeiGene: Consultancy; 4D: Research Funding; Karyopharm: Consultancy; Morphosys: Research Funding; Guardant: Research Funding; Bayer: Consultancy, Research Funding; Genmab: Consultancy; Eastern Cooperative Oncology Group: Research Funding; SeaGen: Consultancy; Genentech/Roche: Consultancy, Research Funding; Pharmacyclics/Janssen: Consultancy; Burroughs Wellcome Fund: Research Funding; AbbVie: Consultancy, Research Funding; Adaptimmune: Research Funding; Janssen: Research Funding; Iovance: Research Funding; Acerta: Research Funding; Kite: Research Funding; Allogene: Research Funding; EMD: Research Funding; Amgen: Research Funding; Celgene: Consultancy, Research Funding; Ziopharm: Research Funding; Novartis: Research Funding; Pfizer: Research Funding; Sanofi: Research Funding; National Cancer Institute: Research Funding; Xencor: Research Funding; Spectrum: Consultancy; Gilead: Consultancy, Research Funding; Epizyme, Inc.: Consultancy; Biopharma: Consultancy; Denovo: Consultancy; Cancer Prevention and Research Institute of Texas: CPRIT Scholar in Cancer Research: Research Funding; Pharmacyclics: Research Funding. Weigert: Janssen: Speakers Bureau; Epizyme: Membership on an entity's Board of Directors or advisory committees; Roche: Research Funding. Herrera: ADC Therapeutics: Consultancy, Research Funding; Tubulis: Consultancy; Karyopharm: Consultancy; Kite, a Gilead Company: Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Gilead Sciences: Research Funding; Merck: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Takeda: Consultancy; Seagen: Consultancy, Research Funding; AstraZeneca: Consultancy, Research Funding. Weinstock: SecuraBio: Consultancy; ASELL: Consultancy; Bantam: Consultancy; Abcuro: Research Funding; Verastem: Research Funding; Daiichi Sankyo: Consultancy, Research Funding; AstraZeneca: Consultancy; Travera: Other: Founder/Equity; Ajax: Other: Founder/Equity. Leonard: ADC Therapeutics, AstraZeneca, Bayer, BMS/Celgene, Epizyme, Inc., Genmab, Gilead/Kite, Karyopharm, BMS/Celgene, Regeneron, MEI Pharma, Miltenyi, Roche/Genentech, Sutro: Consultancy; Roche/Genentech: Consultancy. Kahl: Abbvie, BeiGene, AstraZeneca, Acerta: Research Funding; Research to Practice: Speakers Bureau; Abbvie, ADCT, AstraZeneca, Beigene, Celgene, Teva, Janssen, MTEM, Bayer, InCyte, Adaptive, Genentech, Roche, MEI, KITE, TG Therapeutics, Epizyme, Takeda: Consultancy. Smith: Celgene, Genetech, AbbVie: Consultancy; Alexion, AstraZeneca Rare Disease: Other: Study investigator. Friedberg: Novartis: Other: DSMC ; Acerta: Other: DSMC ; Bayer: Other: DSMC ." @default.
• W3212943903 created "2021-11-22" @default.
• W3212943903 creator A5005159945 @default.
• W3212943903 creator A5015672299 @default.
• W3212943903 creator A5026688095 @default.
• W3212943903 creator A5030788778 @default.
• W3212943903 creator A5037882455 @default.
• W3212943903 creator A5038526399 @default.
• W3212943903 creator A5041539801 @default.
• W3212943903 creator A5041588764 @default.
• W3212943903 creator A5048714300 @default.
• W3212943903 creator A5055100327 @default.
• W3212943903 creator A5069054551 @default.
• W3212943903 creator A5082892912 @default.
• W3212943903 creator A5083450833 @default.
• W3212943903 creator A5089386265 @default.
• W3212943903 date "2021-11-05" @default.
• W3212943903 modified "2023-10-12" @default.
• W3212943903 title "Trial-in-Progress: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (NCT#03269669): SWOG S1608" @default.
• W3212943903 doi "https://doi.org/10.1182/blood-2021-146182" @default.
• W3212943903 hasPublicationYear "2021" @default.
• W3212943903 type Work @default.
• W3212943903 sameAs 3212943903 @default.
• W3212943903 citedByCount "0" @default.
• W3212943903 crossrefType "journal-article" @default.
• W3212943903 hasAuthorship W3212943903A5005159945 @default.
• W3212943903 hasAuthorship W3212943903A5015672299 @default.
• W3212943903 hasAuthorship W3212943903A5026688095 @default.
• W3212943903 hasAuthorship W3212943903A5030788778 @default.
• W3212943903 hasAuthorship W3212943903A5037882455 @default.
• W3212943903 hasAuthorship W3212943903A5038526399 @default.
• W3212943903 hasAuthorship W3212943903A5041539801 @default.
• W3212943903 hasAuthorship W3212943903A5041588764 @default.
• W3212943903 hasAuthorship W3212943903A5048714300 @default.
• W3212943903 hasAuthorship W3212943903A5055100327 @default.
• W3212943903 hasAuthorship W3212943903A5069054551 @default.
• W3212943903 hasAuthorship W3212943903A5082892912 @default.
• W3212943903 hasAuthorship W3212943903A5083450833 @default.
• W3212943903 hasAuthorship W3212943903A5089386265 @default.
• W3212943903 hasConcept C126322002 @default.
• W3212943903 hasConcept C143998085 @default.
• W3212943903 hasConcept C203014093 @default.
• W3212943903 hasConcept C2776063141 @default.
• W3212943903 hasConcept C2776364478 @default.
• W3212943903 hasConcept C2777058707 @default.
• W3212943903 hasConcept C2779015954 @default.
• W3212943903 hasConcept C2779338263 @default.
• W3212943903 hasConcept C2780653079 @default.
• W3212943903 hasConcept C2780790343 @default.
• W3212943903 hasConcept C2781214270 @default.
• W3212943903 hasConcept C2908647359 @default.
• W3212943903 hasConcept C2911091166 @default.
• W3212943903 hasConcept C535046627 @default.
• W3212943903 hasConcept C71924100 @default.
• W3212943903 hasConcept C99454951 @default.
• W3212943903 hasConceptScore W3212943903C126322002 @default.
• W3212943903 hasConceptScore W3212943903C143998085 @default.
• W3212943903 hasConceptScore W3212943903C203014093 @default.
• W3212943903 hasConceptScore W3212943903C2776063141 @default.
• W3212943903 hasConceptScore W3212943903C2776364478 @default.
• W3212943903 hasConceptScore W3212943903C2777058707 @default.
• W3212943903 hasConceptScore W3212943903C2779015954 @default.
• W3212943903 hasConceptScore W3212943903C2779338263 @default.
• W3212943903 hasConceptScore W3212943903C2780653079 @default.
• W3212943903 hasConceptScore W3212943903C2780790343 @default.
• W3212943903 hasConceptScore W3212943903C2781214270 @default.
• W3212943903 hasConceptScore W3212943903C2908647359 @default.
• W3212943903 hasConceptScore W3212943903C2911091166 @default.
• W3212943903 hasConceptScore W3212943903C535046627 @default.
• W3212943903 hasConceptScore W3212943903C71924100 @default.
• W3212943903 hasConceptScore W3212943903C99454951 @default.
• W3212943903 hasIssue "Supplement 1" @default.
• W3212943903 hasLocation W32129439031 @default.
• W3212943903 hasOpenAccess W3212943903 @default.
• W3212943903 hasPrimaryLocation W32129439031 @default.
• W3212943903 hasRelatedWork W2043921099 @default.
• W3212943903 hasRelatedWork W2102241654 @default.
• W3212943903 hasRelatedWork W2126113018 @default.
• W3212943903 hasRelatedWork W2308455367 @default.
• W3212943903 hasRelatedWork W2366724976 @default.
• W3212943903 hasRelatedWork W2979596396 @default.
• W3212943903 hasRelatedWork W2981884153 @default.
• W3212943903 hasRelatedWork W3014926372 @default.
• W3212943903 hasRelatedWork W3197673475 @default.
• W3212943903 hasRelatedWork W3212943903 @default.
• W3212943903 hasVolume "138" @default.
• W3212943903 isParatext "false" @default.
• W3212943903 isRetracted "false" @default.
• W3212943903 magId "3212943903" @default.
• W3212943903 workType "article" @default.